Clinical Trials
Dyax reports interim analysis data of Phase 2 ecallantide trial
Dyax has reported interim analysis results of Phase 2 trial of ecallantide for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema. Based on the data from interim analysis the company decided to discontinue...
Clinical Trials
Quest PharmaTech to start Phase II Oregovomab clinical trial
Quest PharmaTech has got clearance from FDA to initiate US sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients. The aim of the trial will be to...
Clinical Trials
Bayer, Onyx Phase III NSCLC trial fails to meet primary endpoint
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that Phase III trial of Nexavar  in non-small cell lung cancer patients did not meet primary endpoint of improving overall survival. The Monotherapy admInistration of Sorafenib...
Clinical Trials
Active Biotech, Ipsen reach EUR10m milestone in Phase III study of tasquinimod
Active Biotech and Ipsen have announced the recruitment of 600 patients in randomized, placebo-controlled Phase III study of tasquinimod in metastatic castrate-resistant prostate cancer patients. The recruitment of half of target patient population triggered...
Clinical Trials
Peregrine reports results from phase II front-line lung cancer trial
Peregrine Pharmaceuticals has announced results from its randomized phase II trial, which is designed to determine overall response rate of carboplatin and paclitaxel with or without bavituximab in 86 patients with front-line, Stage IIIb and Stage IV non-small...
Clinical Trials
Circassia reports positive results from Phase II ragweed allergy therapy study
 Circassia, a specialty biopharmaceutical company, has announced positive results from Phase II clinical trial of ragweed allergy therapy.  According to the study, patients with more severe symptoms achieved a greater improvement following treatment with...
Clinical Trials
PhaseBio begins Phase I hypertension study with Vasomera
PhaseBio Pharmaceuticals, a biotechnology company, has initiated Phase I clinical study with its novel compound, Vasomera (PB1046), in patients with Stage 1 and 2 essential hypertension. The primary objective of the placebo-controlled study is...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read